Company news
NeuroSense Therapeutics Ltd. news in 2024
NeuroSense Therapeutics Ltd.'s news releases, calls and decks from 2024, newest first.
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
December 22, 2024
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
December 17, 2024
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
December 10, 2024
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
December 3, 2024
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
December 1, 2024
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
November 20, 2024
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
October 27, 2024
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
October 23, 2024
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market
October 16, 2024
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
October 14, 2024
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
October 8, 2024
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
October 6, 2024
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
September 23, 2024
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
September 23, 2024
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
August 29, 2024
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
August 6, 2024
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial
July 31, 2024
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
July 8, 2024
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug
June 30, 2024
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
June 23, 2024
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
June 20, 2024
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit
May 19, 2024
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
May 13, 2024
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
May 6, 2024
NeuroSense Announces First Quarter 2024 Business Update
May 1, 2024
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
April 21, 2024
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
April 17, 2024
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
April 11, 2024
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
April 9, 2024
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
April 8, 2024
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
April 4, 2024
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
February 20, 2024
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
January 8, 2024
Decks in 2024
- Investor Presentation (April 2024)
Investor deck · 42 slides · Apr 10, 2024
- Investor Presentation (February 2024)
Investor deck · 40 slides · Feb 22, 2024
- Investor Presentation (January 2024)
Investor deck · 33 slides · Jan 9, 2024